The CEO of Marseille based ImCheck Therapeutics on targeting butyrophilin to modulate innate and adaptive immunity

blonca9
Sep 6, 2024
1 min read

Pierre d'Epenoux describes how activating butyrophilin modulates γδ t-cells, science that has largely been explored in Marseille, and covers ImCheck's current clinical programs. Plus, what it is like being a biotech company in this area.

Recent Posts

See All

Checking in with MoonLake's CEO ahead of one of biotech's most closely watched trial readouts of the year - the phase 3 VELA program of sonelokimab in HS (due in Sept)

KalVista's CEO discusses today's FDA approval and commercial launch of Ekterly, the first oral therapy for treating hereditary angioedema (HAE) attacks

AI News: Singapore based Gero, a company focused on small molecules for aging conditions, launched ProtoBind-Diff, a model using amino acid sequences rather than structure models for discovery

The CEO of Marseille based ImCheck Therapeutics on targeting butyrophilin to modulate innate and adaptive immunity

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight